PMID- 17321896
OWN - NLM
STAT- MEDLINE
DCOM- 20070608
LR  - 20171116
IS  - 0198-8859 (Print)
IS  - 0198-8859 (Linking)
VI  - 68
IP  - 2
DP  - 2007 Feb
TI  - Activated B cells mediate efficient expansion of rare antigen-specific T cells.
PG  - 75-85
AB  - Potent professional antigen-presenting cells (APC) are essential tools to 
      activate and expand antigen-specific T cells in vitro for use in adoptive 
      immunotherapy. CD40-activated B cells can be easily generated and propagated from 
      human donors and have been successfully used to generate antigen-specific T-cell 
      cultures. Here we show that CD40-activated B cells strongly and specifically 
      expand rare populations of antigen-specific CD8 T cells, with frequencies of less 
      than 1 in 20,000 CD8 T cells in peripheral blood. We focused on T cells 
      recognizing an epitope from the human papillomavirus 16 (HPV-16) E7 protein. In 6 
      of 6 healthy donors, epitope-specific CD8+ T cells were found to be "rare" by 
      this criterion, as shown by staining with human leukocyte antigen (HLA)/peptide 
      multimers. Using peptide-loaded CD40-activated B cells, epitope-specific T cells 
      could be selectively expanded in all donors up to 10(6) fold, and the resulting 
      T-cell cultures contained up to 88% specific T cells. These results strongly 
      encourage the use of CD40-stimulated B cells as APCs in immunotherapy.
FAU - Zentz, Caroline
AU  - Zentz C
AD  - Clinical Cooperative Group Molecular Oncology, GSF - National Research Center for 
      Environment and Health, Munich, Germany.
FAU - Wiesner, Martina
AU  - Wiesner M
FAU - Man, Stephen
AU  - Man S
FAU - Frankenberger, Bernhard
AU  - Frankenberger B
FAU - Wollenberg, Barbara
AU  - Wollenberg B
FAU - Hillemanns, Peter
AU  - Hillemanns P
FAU - Zeidler, Reinhard
AU  - Zeidler R
FAU - Hammerschmidt, Wolfgang
AU  - Hammerschmidt W
FAU - Moosmann, Andreas
AU  - Moosmann A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070108
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (CD40 Antigens)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Oncogene Proteins, Viral)
RN  - 0 (Papillomavirus E7 Proteins)
RN  - 0 (oncogene protein E7, Human papillomavirus type 16)
SB  - IM
MH  - Antigen-Presenting Cells/immunology
MH  - B-Lymphocytes/*immunology
MH  - CD40 Antigens/immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cells, Cultured
MH  - Epitopes, T-Lymphocyte/immunology
MH  - HLA-A2 Antigen/immunology
MH  - Humans
MH  - Immunotherapy/methods
MH  - Lymphocyte Activation
MH  - Oncogene Proteins, Viral/chemical synthesis/immunology
MH  - Papillomavirus E7 Proteins
MH  - Species Specificity
MH  - T-Lymphocyte Subsets/immunology
EDAT- 2007/02/27 09:00
MHDA- 2007/06/09 09:00
CRDT- 2007/02/27 09:00
PHST- 2006/07/31 00:00 [received]
PHST- 2006/12/08 00:00 [accepted]
PHST- 2007/02/27 09:00 [pubmed]
PHST- 2007/06/09 09:00 [medline]
PHST- 2007/02/27 09:00 [entrez]
AID - S0198-8859(06)00611-2 [pii]
AID - 10.1016/j.humimm.2006.12.004 [doi]
PST - ppublish
SO  - Hum Immunol. 2007 Feb;68(2):75-85. doi: 10.1016/j.humimm.2006.12.004. Epub 2007 
      Jan 8.